Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia

Blood (2025) 146 (Supplement 1): 5922.

https://doi.org/10.1182/blood-2025-5922

Published: 2025

Journal Articles

The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors

Lei Ye, Xin Zhao, fengkui zhang, Li Zhang

Blood (2025) 146 (Supplement 1): 4971.

https://doi.org/10.1182/blood-2025-4971

Published: 2025

Journal Articles

Real-world evidence from China: Clinical characteristics, treatment landscape and long-term outcomes in 566 autoimmune hemolytic anemia patients

Junan Zhang, Jiewen Qiu, Yizhou Zheng, Fengkui Zhang, Jun Shi, Xin Zhao

Blood (2025) 146 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2025-2878

Published: 2025

Journal Articles

First-line romiplostim combined with immunosuppressive therapy for severe aplastic anemia: A prospective, single-arm, Phase II study

Blood (2025) 146 (Supplement 1): 1426.

https://doi.org/10.1182/blood-2025-1426

Published: 2025

Journal Articles

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

Pingnan Xiao, Xin Zhao, Linqin Wang, Yixue Li, Mingming Zhang, Jingjing Feng, Shan Fu, Houli Zhao, Kui zhao, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5855.

https://doi.org/10.1182/blood-2025-5855

Published: 2025

Journal Articles

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia

Zhen Gao, Hong Pan, Lele Zhang, Weiwang Li, Ruonan Li, Jingyu Zhao, Yuechen Luo, Yu Lian, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Yuan Li, Liwei Fang, Meili Ge, Yizhou Zheng, Jun Shi

Blood (2025) 145 (26): 3189–3193.

https://doi.org/10.1182/blood.2025029006

Published: 2025

Includes: Supplemental data

Journal Articles

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

Nichola Cooper, David J Kuter, Henrik Frederiksen, Bing Han, Frederick Chen, Wilma Barcellini, Joan Cid, Catherine M. Broome, Míriam Vara, Amitabha Mazumder, Alessandro Lucchesi, Xin Zhao, Antonio M Risitano, Sumit Sawhney, Quentin A. Hill, Deepthi Jayawardene, Remco Diab, Jing Zhao, Ahmed Daak

Blood (2024) 144 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2024-200325

Published: 2024

Journal Articles

Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study

Fengkui Zhang, Bing Han, Li Zhang, Xin Zhao

Blood (2024) 144 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2024-201147

Published: 2024

Journal Articles

Recombinant Human Thrombopoietin Add to IST Combined with Hetrombopag As First-Line Treatment for Naïve Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Huihui Fan, Wenrui Yang, Xin Zhao, Li Zhang, Liping Jing, Fengkui Zhang

Blood (2024) 144 (Supplement 1): 4086.

https://doi.org/10.1182/blood-2024-207840

Published: 2024

Journal Articles

Cyclophosphamide Combined with Standard Immunosuppressive Therapy Improves Early Response Outcomes in Severe Aplastic Anemia

Hong Pan, Lele Zhang, Zhen Gao, Weiwang Li, Jianping Li, Neng Nie, Youzhen Xiong, Xin Zhao, Jinbo Huang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Liwei Fang, Meili Ge, Weiping Yuan, Jun Shi

Blood (2024) 144 (Supplement 1): 5685.

https://doi.org/10.1182/blood-2024-205532

Published: 2024

Journal Articles

Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail

Zhen Gao, Hong Pan, Jinbo Huang, Xin Zhao, Lele Zhang, Weiwang Li, Jianping Li, Neng Nie, Jingyu Zhao, Liyun Li, Jing Xu, Xiao Yu, Zhexiang Kuang, Meili Ge, Liwei Fang, Jun Shi

Blood (2024) 144 (Supplement 1): 4029.

https://doi.org/10.1182/blood-2024-204858

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Hetrombopag, an Emerging Iron-Chelating Agent, Alleviates Systemic Iron Overload

Zhao Yufei, Xin Zhao, Wenrui Yang, Fengkui Zhang

Blood (2024) 144 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2024-201638

Published: 2024

Journal Articles

Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia

Weiwang Li, Lele Zhang, Hong Pan, Zhen Gao, Jianping Li, Neng Nie, Xin Zhao, Jinbo Huang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Liwei Fang, Meili Ge, Weiping Yuan, Jun Shi

Blood (2024) 144 (Supplement 1): 2697.

https://doi.org/10.1182/blood-2024-207110

Published: 2024

Journal Articles

Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD

Ying Wang, Shan He, Gennaro Calendo, Tien Bui, Yuanyuan Tian, Che Young Lee, Yan Zhou, Xin Zhao, Ciril Abraham, Wenbin Mo, Mimi Chen, Ruqayyah Sanders-Braggs, Jozef Madzo, Jean-Pierre Issa, Elizabeth O. Hexner, David L. Wiest, Ran Reshef, Hai-Hui Xue, Yi Zhang

Blood (2024) 143 (2): 166–177.

https://doi.org/10.1182/blood.2023021126

Published: 2024

Includes: Supplemental data

Journal Articles

Early Efficacy of IST in Combination with Hetrombopag and Rhtpo As First-Line Treatment for Naïve Severe Aplastic Anemia

Huihui Fan, Wenrui Yang, Xin Zhao, Li Zhang, Youzhen Xiong, Liping Jing, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 5634.

https://doi.org/10.1182/blood-2023-182794

Published: 2023

Journal Articles

The Role of Red Blood Cell Lifespan Testing in the Evaluation of Patients with Paroxysmal Nocturnal Hemoglobinuria

Lei Ye, Xin Zhao, Liping Jing, Fengkui Zhang, Li Zhang

Blood (2023) 142 (Supplement 1): 5652.

https://doi.org/10.1182/blood-2023-181404

Published: 2023

Journal Articles

Myopathy with Lactic Acidosis and Sideroblastic Anemia Caused By a Novel PUS1 mutation

Youzhen Xiong, Wenrui Yang, Huihui Fan, Li Zhang, Xin Zhao, Liping Jing, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 5242.

https://doi.org/10.1182/blood-2023-182770

Published: 2023

Journal Articles

Comparison between Hetrombopag and Eltrombopag Combined with IST As First-Line Treatment for Severe Aplastic Anemia

Wenrui Yang, Baohang Zhang, Xiangrong Hu, Li Zhang, Liping Jing, Xin Zhao, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2023-186123

Published: 2023

Journal Articles

Avatrombopag Is Effective in First-Line Treatment of Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Xin Zhao, Jianping Li, Huihui Fan, Liping Jing, Li Zhang, Kang Zhou, Wenrui Yang, Yuan Li, Yang Yang, Lei Ye, Guangxin Peng, Youzhen Xiong, Jun Shi, Fengkui Zhang

Blood (2023) 142 (Supplement 1): 4087.

https://doi.org/10.1182/blood-2023-190948

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia

The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors

Real-world evidence from China: Clinical characteristics, treatment landscape and long-term outcomes in 566 autoimmune hemolytic anemia patients

First-line romiplostim combined with immunosuppressive therapy for severe aplastic anemia: A prospective, single-arm, Phase II study

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia

Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study

Recombinant Human Thrombopoietin Add to IST Combined with Hetrombopag As First-Line Treatment for Naïve Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Cyclophosphamide Combined with Standard Immunosuppressive Therapy Improves Early Response Outcomes in Severe Aplastic Anemia

Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Hetrombopag, an Emerging Iron-Chelating Agent, Alleviates Systemic Iron Overload

Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia

Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD

Early Efficacy of IST in Combination with Hetrombopag and Rhtpo As First-Line Treatment for Naïve Severe Aplastic Anemia

The Role of Red Blood Cell Lifespan Testing in the Evaluation of Patients with Paroxysmal Nocturnal Hemoglobinuria

Myopathy with Lactic Acidosis and Sideroblastic Anemia Caused By a Novel PUS1 mutation

Comparison between Hetrombopag and Eltrombopag Combined with IST As First-Line Treatment for Severe Aplastic Anemia

Avatrombopag Is Effective in First-Line Treatment of Severe Aplastic Anemia: Early Outcomes of a Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only